Zydus Life Desidustat gets CDSCO panel nod to treat Anaemia in Kidney Patients
Advertisement
New Delhi: In a significant development, Zydus Life has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market Desidustat Tablet for the treatment of Anaemia in adult patients with chronic kidney disease(CKD).
This came in line with proposal presented by the drug maker Zydus Life to manufacture and market the Desidustat Tablets 100 mg for the treatment of Anaemia in adult patients with chronic kidney disease(CKD) not on dialysis and on dialysis along with the justification of Bioequivalence (BE) study waiver.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.